Familial adenomatous polyposis
Conditions
Interventions
6 months oral administration of time-dependent release mesalazine 4g/day (2g twice daily).
Sponsors
Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who need colonoscopic examination at least once a half year
Exclusion criteria
Exclusion criteria: 1) Patients who take mesalamine or sulphasalazine within two weeks before the registration. 2) Patients who have possibility to take NSAIDs (non-steroidal anti-inflammatory drugs) constantly during the study period. 3) Patients who have high possibility to be applied colectomy during the study period. 4) Patients with hypersensitivity to salicylic acid drug or mesalazine formulations. 5) Patients who have experienced serious adverse events due to mesalazine. 6) Women who are or may be pregnant during the study period. 7) Patients with side effects by other previous clinical studies. 8) Patients who were considered unsuitable for this study by investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the size of colorectal polyps post administration to that at baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| Below items are compared between pre and post administration of mesalazine. number of colorectal polyps, sites of polyps, adverse events, size and number of polyps (fundic gland polyp, gastric adenoma (gastric, intestinal type), duodenal adenoma, thyroid tumor, gallbladder polyp, desmoids). | — |
Countries
Japan
Contacts
Public ContactHideki Ishikawa MD, PhD
Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Department of Molecular-Targeting Cancer Prevention
Outcome results
None listed